Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292772 · ClinicalTrials.gov registry record
The Effects of Radiation in Reconstructed Breasts
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 12
- Enrollment target
NCT01292772: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01292772 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01292772 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The primary objective of this study is to use LR imaging to evaluate the effects of adjuvant radiation therapy on reconstructed breasts.
Primary Outcome
This will be compared at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
Interventions
- PROCEDURE contract-enhanced MRI
- RADIATION Unilateral Adjuvant Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-12 |
| Est. Completion | 2019-05-05 |
What the finished NCT01292772 record still lists
NCT01292772 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which contract-enhanced MRI is the first listed.
NCT01292772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01292772 about?
NCT01292772 is a clinical study titled "The Effects of Radiation in Reconstructed Breasts". The primary objective of this study is to use LR imaging to evaluate the effects of adjuvant radiation therapy on reconstructed breasts.
What is the current status of trial NCT01292772?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2010-12. Estimated completion is 2019-05-05.
What interventions are being tested in trial NCT01292772?
The interventions under investigation include: contract-enhanced MRI (PROCEDURE), Unilateral Adjuvant Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01292772?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia